• Je něco špatně v tomto záznamu ?

Modulation of induced cytotoxicity of doxorubicin by using apoferritin and liposomal cages

J. Gumulec, M. Fojtu, M. Raudenska, M. Sztalmachova, A. Skotakova, J. Vlachova, S. Skalickova, L. Nejdl, P. Kopel, L. Knopfova, V. Adam, R. Kizek, M. Stiborova, P. Babula, M. Masarik,

. 2014 ; 15 (12) : 22960-77. [pub] 20141211

Jazyk angličtina Země Švýcarsko

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc15031583

Doxorubicin is an effective chemotherapeutic drug, however, its toxicity is a significant limitation in therapy. Encapsulation of doxorubicin inside liposomes or ferritin cages decreases cardiotoxicity while maintaining anticancer potency. We synthesized novel apoferritin- and liposome-encapsulated forms of doxorubicin ("Apodox" and "lip-8-dox") and compared its toxicity with doxorubicin and Myocet on prostate cell lines. Three different prostatic cell lines PNT1A, 22Rv1, and LNCaP were chosen. The toxicity of the modified doxorubicin forms was compared to conventional doxorubicin using the MTT assay, real-time cell impedance-based cell growth method (RTCA), and flow cytometry. The efficiency of doxorubicin entrapment was 56% in apoferritin cages and 42% in the liposome carrier. The accuracy of the RTCA system was verified by flow-cytometric analysis of cell viability. The doxorubicin half maximal inhibition concentrations (IC50) were determined as 170.5, 234.0, and 169.0 nM for PNT1A, 22Rv1, and LNCaP, respectively by RTCA. Lip8-dox is less toxic on the non-tumor cell line PNT1A compared to doxorubicin, while still maintaining the toxicity to tumorous cell lines similar to doxorubicin or epirubicin (IC50 = 2076.7 nM for PNT1A vs. 935.3 and 729.0 nM for 22Rv1 and LNCaP). Apodox IC50 was determined as follows: 603.1, 1344.2, and 931.2 nM for PNT1A, 22Rv1, and LNCaP.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc15031583
003      
CZ-PrNML
005      
20161214103437.0
007      
ta
008      
151005s2014 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3390/ijms151222960 $2 doi
035    __
$a (PubMed)25514405
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Gumulec, Jaromir $u Department of Pathological Physiology, Faculty of Medicine, Masaryk University, Kamenice 5, CZ-62500 Brno, Czech Republic. j.gumulec@gmail.com.
245    10
$a Modulation of induced cytotoxicity of doxorubicin by using apoferritin and liposomal cages / $c J. Gumulec, M. Fojtu, M. Raudenska, M. Sztalmachova, A. Skotakova, J. Vlachova, S. Skalickova, L. Nejdl, P. Kopel, L. Knopfova, V. Adam, R. Kizek, M. Stiborova, P. Babula, M. Masarik,
520    9_
$a Doxorubicin is an effective chemotherapeutic drug, however, its toxicity is a significant limitation in therapy. Encapsulation of doxorubicin inside liposomes or ferritin cages decreases cardiotoxicity while maintaining anticancer potency. We synthesized novel apoferritin- and liposome-encapsulated forms of doxorubicin ("Apodox" and "lip-8-dox") and compared its toxicity with doxorubicin and Myocet on prostate cell lines. Three different prostatic cell lines PNT1A, 22Rv1, and LNCaP were chosen. The toxicity of the modified doxorubicin forms was compared to conventional doxorubicin using the MTT assay, real-time cell impedance-based cell growth method (RTCA), and flow cytometry. The efficiency of doxorubicin entrapment was 56% in apoferritin cages and 42% in the liposome carrier. The accuracy of the RTCA system was verified by flow-cytometric analysis of cell viability. The doxorubicin half maximal inhibition concentrations (IC50) were determined as 170.5, 234.0, and 169.0 nM for PNT1A, 22Rv1, and LNCaP, respectively by RTCA. Lip8-dox is less toxic on the non-tumor cell line PNT1A compared to doxorubicin, while still maintaining the toxicity to tumorous cell lines similar to doxorubicin or epirubicin (IC50 = 2076.7 nM for PNT1A vs. 935.3 and 729.0 nM for 22Rv1 and LNCaP). Apodox IC50 was determined as follows: 603.1, 1344.2, and 931.2 nM for PNT1A, 22Rv1, and LNCaP.
650    _2
$a zvířata $7 D000818
650    _2
$a antibiotika antitumorózní $x aplikace a dávkování $x chemie $x toxicita $7 D000903
650    12
$a apoferritiny $7 D001052
650    _2
$a nádorové buněčné linie $7 D045744
650    _2
$a viabilita buněk $x účinky léků $7 D002470
650    _2
$a vztah mezi dávkou a účinkem léčiva $7 D004305
650    _2
$a doxorubicin $x aplikace a dávkování $x chemie $x toxicita $7 D004317
650    _2
$a nosiče léků $7 D004337
650    _2
$a příprava léků $7 D004339
650    _2
$a koně $7 D006736
650    _2
$a lidé $7 D006801
650    _2
$a inhibiční koncentrace 50 $7 D020128
650    12
$a liposomy $7 D008081
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Fojtu, Michaela $u Department of Pathological Physiology, Faculty of Medicine, Masaryk University, Kamenice 5, CZ-62500 Brno, Czech Republic. michaelafojtu@gmail.com.
700    1_
$a Raudenska, Martina $u Department of Pathological Physiology, Faculty of Medicine, Masaryk University, Kamenice 5, CZ-62500 Brno, Czech Republic. 42700@mail.muni.cz.
700    1_
$a Sztalmachova, Marketa $u Department of Pathological Physiology, Faculty of Medicine, Masaryk University, Kamenice 5, CZ-62500 Brno, Czech Republic. sztalm@med.muni.cz.
700    1_
$a Skotakova, Anna $u Department of Pathological Physiology, Faculty of Medicine, Masaryk University, Kamenice 5, CZ-62500 Brno, Czech Republic. 424299@mail.muni.cz.
700    1_
$a Vlachova, Jana $u Central European Institute of Technology, Brno University of Technology, Technicka 3058/10, CZ-61600 Brno, Czech Republic. vlachova.jana@centrum.cz.
700    1_
$a Skalickova, Sylvie $u Central European Institute of Technology, Brno University of Technology, Technicka 3058/10, CZ-61600 Brno, Czech Republic. sylvie.skalickova@gmail.com.
700    1_
$a Nejdl, Lukas $u Central European Institute of Technology, Brno University of Technology, Technicka 3058/10, CZ-61600 Brno, Czech Republic. lukasnejdl@gmail.com.
700    1_
$a Kopel, Pavel $u Central European Institute of Technology, Brno University of Technology, Technicka 3058/10, CZ-61600 Brno, Czech Republic. paulko@centrum.cz.
700    1_
$a Knopfová, Lucia $u Department of Experimental Biology, Faculty of Science, Masaryk University, Kamenice 5, CZ-62500 Brno, Czech Republic. l.knopfova@seznam.cz. $7 xx0208986
700    1_
$a Adam, Vojtěch $u Central European Institute of Technology, Brno University of Technology, Technicka 3058/10, CZ-61600 Brno, Czech Republic. vojtech.adam@mendelu.cz. $7 xx0064599
700    1_
$a Kizek, Rene $u Central European Institute of Technology, Brno University of Technology, Technicka 3058/10, CZ-61600 Brno, Czech Republic. kizek@sci.muni.cz.
700    1_
$a Stiborova, Marie $u Department of Biochemistry, Faculty of Science, Charles University, Albertov 2030, CZ-12840 Prague 2, Czech Republic. stiborov@natur.cuni.cz.
700    1_
$a Babula, Petr $u Department of Physiology, Faculty of Medicine, Masaryk University, Kamenice 5, CZ-62500 Brno, Czech Republic. babula@med.muni.cz.
700    1_
$a Masarik, Michal $u Department of Pathological Physiology, Faculty of Medicine, Masaryk University, Kamenice 5, CZ-62500 Brno, Czech Republic. masarik@med.muni.cz.
773    0_
$w MED00176142 $t International journal of molecular sciences $x 1422-0067 $g Roč. 15, č. 12 (2014), s. 22960-77
856    41
$u https://pubmed.ncbi.nlm.nih.gov/25514405 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20151005 $b ABA008
991    __
$a 20161214103455 $b ABA008
999    __
$a ok $b bmc $g 1092459 $s 914709
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2014 $b 15 $c 12 $d 22960-77 $e 20141211 $i 1422-0067 $m International journal of molecular sciences $n Int J Mol Sci $x MED00176142
LZP    __
$a Pubmed-20151005

Najít záznam

Citační ukazatele

Možnosti archivace